Lincoln Pharmaceuticals Ltd · NSE:LINCOLN
Lincoln Pharmaceuticals — Q3 FY2016 Earnings Presentation
18 slides from Lincoln Pharmaceuticals's earnings presentation, March 2016
Slide 1: Q3 FY2016 Earnings Presentation
Providing Affordable and Innovative medicines for healthier lives Q3 FY2016 Earnings Presentation March 2016
Slide 2: Highlights of the Quarter
Highlights of the Quarter 9M FY2016 vs. 9M FY2015 Management Perspective o Net Revenue of Rs. 2,790 million, up 43.3% “We are pleased to announce a stellar performance with over 40% o EBITDA of Rs. 363 million, up 42.5% growth in our revenue during the nine months of the fiscal year. Our EBITDA ma
Slide 3: Performance Overview
Performance Overview Consolidated Financial Performance Q3 y-o-y Q2 q-o-q Nine Months y-o-y Particulars (Rs. million) FY2016 FY2015 Growth (%) FY2016 Growth (%) FY2016 FY2015 Growth (%) Net Revenue 1,080 675 59.9% 954 13.2% 2,790 1,947 43.3% EBITDA 132 63 107.5% 117 12.3% 363 255 42.5% Margin (%) 12
Slide 4: Performance Overview: Revenue Breakup
Performance Overview Revenue Breakup 1.9% 1.1%1.5% 3% 2% 1% 1.9% 2.0% 1% General Anti Infectives 5% 1.1% 3.2% 3.2% 23% 5.2% 4.9% Respiratory Systems 24.9% 11% 24.6% Therapeutic Area Alimentary Tract and Metabolism 11.6% 11.3% 13% Genito Urinary System and Sex Hormones Q3 Q3 22% Musculo-Skeletal Syst
Slide 5: Performance Trend
Performance Trend Net Revenue (Rs. Million) and Y-o-Y Growth (%) Highlights 54.1% 59.9% 27.5% 17.7% 22.2% o Our robust revenue growth was driven by 675 786 757 954 1,080 strong performance across all therapeutic Q3 FY15 Q4 FY15 Q1 FY16 Q2 FY16 Q3 FY16 areas EBITDA (Rs. Million) and Margin (%) o Perf
Slide 6: Leverage Profile
Leverage Profile (Rs. million) 31-Dec-2015 30-Sep-2015 Credit Rating Long Term Debt 226 226 o The Company’s debt facilities have been assigned the following ratings by CRISIL Short Term Debt 417 412 Long term bank facilities: A- Total Debt 643 638 Short term bank facilities: A2+ Less: Cash & Cas
Slide 7: Strategic Initiatives
Strategic Initiatives 1 New Launches • Launched the Dermatology Division with a team of approximately 50 people • Introduced 15 products under this division 2 Capacity expansion • Completed the expansion of Unit 1 (Tablet, Capsule & Ointment), which resulted in trebling of the current capacity • Als
Slide 8: A Leading Pharmaceutical Company
A Leading Pharmaceutical Company 15+ 44th 773 Registered Dossiers Rank in AIOCD Therapeutic Areas July 2014 in covered markets 580 Ongoing Applications 1000+ 500+ Registered Products SKUs 5000 Stockiest 300+ 22 C&F Agents Formulations Developed 4 Patents Granted 30+ 550 Field Staff 25 Patents Applic
Slide 9: Key Milestones
Key Milestones Received WHO – GMP Becomes Public Covered 80% of all Developed & for plant/production Limited Company India Market Launched 3 NDDS unit from a Partnership products 2014-15 2001 2010-11 1997-98 2000 1990 1995-96 1984-85 1979 1979 Started export to R&D Center started; Tanzania and Domes
Slide 10: Global Footprint
Global Footprint Presence over 50 countries in Latin America, Africa and Asia Pacific; 22 states across India Jammu Uttaranchal Chandigarh Delhi Ambala Ghaziabad Lucknow Guwahati Jaipur Patna Ranchi Ahmedabad Kolkata Indore Raipur Nagpur Cuttack Vijayawada Chennai Latin & Central America : East & We
Slide 11: Best-in-Class Facilities
Best-in-Class Facilities Certifications: WHO-GMP Certified; ISO9001:2008 Certified R&D Center: Approved by Government of India; Team of 30 scientists for R&D Green Energy: Windmill project for energy saving Dosage Forms Produced at Unit 1 Dosage Forms Produced at Unit 2 Description Annual Capacity U
Slide 12: Wide Spectrum of Therapeutic Coverage
Wide Spectrum of Therapeutic Coverage Cough & Cold / Anti Allergic / Anti-asthmatics Others* ᵦ - lactams Gyneacologial Products Analgesic / Anti-pyretic Therapies covered Gastro Intestinal Range Anti-bacterial / Anti-viral Vitamins / Minerals / Anti-malarial Anti-oxidants * Other therapies include A
Slide 13: Key Brands – Domestic Markets
Key Brands – Domestic Markets Each squirts (spray) delivers 2 mg Ondansetron Hydrochloride Nimesulide 100 mg + Loratidine 5 mg + Ambroxol 30 mg + Phenylephrine 20 mg Sustain Release Tablets 2 Caroverine 160 mg/8 ml 1 3 Injection Natural micronized Effective Anti- Malarial Kingping 12 4 progesterone
Slide 14: Key Brands – International Markets
Key Brands – International Markets 1000 mg programmed release Paracetamol PROGLETS Fluconazole 150 mg Tablets 2 1 3 Artesunate 60 mg Injectable Anti Cold Capsules 12 4 Glimepiride 1mg/2 ml Tablets 11 5 α-β Arteether Injection 150mg/ 2 ml Clotrimazole 2% w/w Cream 10 6 Ibuprofen 50 mg + Paracetamol L
Slide 15: Key Recent Developments
Key Recent Developments o Paracetamol 1000 mg programmed release tablet • Unique bi layered proglet designed for programmed release drug delivery • 12 hours action with 30% IR and 70% SR release activity • BID with more patient compliance and is Hepato-friendly o Caroverine injection • Sterile formu
Slide 16: Key Recent Developments
Key Recent Developments o Namcold DX • First time in India: ‘Extended Release’ Oral Suspension • The only liquid cough suppressant that works for upto 12 hours • BID dose with more patient compliance • Available in alcohol free delicious orange flavor o Domi Up Spray • Meter dose pump • Each squirt
Slide 17: Disclaimer
Disclaimer This presentation contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Lincoln Pharmaceuticals’ future business developments and economic perfor
Slide 18: Corporate Office: Lincoln Pharmaceuticals Limited
Corporate Office: Lincoln Pharmaceuticals Limited CIN: L24230GJ1995PLC024288 Lincoln House B/h Satyam Complex, Science City Road, Sola, Ahmedabad – 380 062 Phone: +91 79 6777 8000 • Fax:+91 79 6777 8062 • E-mail: info@lincolnpharma.com KP Sompura, Finance Head sompurakp@lincolnpharma.com Lincoln Pha
Lincoln Pharmaceuticals — Q3 FY2016 Earnings Presentation on 6ix